Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
      COVID-19*/diagnosis ; COVID-19*/epidemiology; Antibodies, Viral/*analysis ; Ethnicity/*statistics & numerical data; Adolescent ; Adult ; Bias ; California/epidemiology ; Female ; Humans ; Immunoglobulin G/analysis ; Immunoglobulin M/analysis ; Male ; Middle Aged ; Prevalence ; Public Health Surveillance ; Seroepidemiologic Studies ; Young Adult
    • نبذة مختصرة :
      Clinic-based estimates of SARS-CoV-2 may considerably underestimate the total number of infections. Access to testing in the US has been heterogeneous and symptoms vary widely in infected persons. Public health surveillance efforts and metrics are therefore hampered by underreporting. We set out to provide a minimally biased estimate of SARS-CoV-2 seroprevalence among adults for a large and diverse county (Orange County, CA, population 3.2 million). We implemented a surveillance study that minimizes response bias by recruiting adults to answer a survey without knowledge of later being offered SARS-CoV-2 test. Several methodologies were used to retrieve a population-representative sample. Participants (n = 2979) visited one of 11 drive-thru test sites from July 10th to August 16th, 2020 (or received an in-home visit) to provide a finger pin-prick sample. We applied a robust SARS-CoV-2 Antigen Microarray technology, which has superior measurement validity relative to FDA-approved tests. Participants include a broad age, gender, racial/ethnic, and income representation. Adjusted seroprevalence of SARS-CoV-2 infection was 11.5% (95% CI: 10.5-12.4%). Formal bias analyses produced similar results. Prevalence was elevated among Hispanics (vs. other non-Hispanic: prevalence ratio [PR] = 1.47, 95% CI 1.22-1.78) and household income < $50,000 (vs. > $100,000: PR = 1.42, 95% CI: 1.14 to 1.79). Results from a diverse population using a highly specific and sensitive microarray indicate a SARS-CoV-2 seroprevalence of ~ 12 percent. This population-based seroprevalence is seven-fold greater than that using official County statistics. In this region, SARS-CoV-2 also disproportionately affects Hispanic and low-income adults.
    • References:
      Nat Commun. 2021 Jan 4;12(1):6. (PMID: 33397903)
      JAMA Intern Med. 2020 Jul 21;:. (PMID: 32692365)
      Ann Epidemiol. 2020 Aug;48:23-29.e4. (PMID: 32648546)
      N Engl J Med. 2020 Mar 26;382(13):1268-1269. (PMID: 32109011)
      Lancet Infect Dis. 2020 May;20(5):533-534. (PMID: 32087114)
      Annu Rev Public Health. 2017 Mar 20;38:57-79. (PMID: 27992726)
      JAMA. 2020 May 19;323(19):1891-1892. (PMID: 32293639)
      Health Serv Res. 2013 Jun;48(3):905-12. (PMID: 23656501)
      Int J Epidemiol. 2021 May 17;50(2):410-419. (PMID: 33615345)
      JAMA. 2020 Jul 28;324(4):392-395. (PMID: 32556212)
      Health Serv Res. 2013 Jun;48(3):913-30. (PMID: 23046097)
      MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):960-964. (PMID: 32701938)
      Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22035-22041. (PMID: 32820077)
      JAMA. 2020 Jun 16;323(23):2425-2427. (PMID: 32421144)
      Nat Med. 2020 Aug;26(8):1200-1204. (PMID: 32555424)
      Bull World Health Organ. 2021 Jan 01;99(1):19-33F. (PMID: 33716331)
      J Vis Exp. 2019 Jul 26;(149):. (PMID: 31403629)
      Science. 2020 Apr 24;368(6489):350-351. (PMID: 32327574)
      Lancet. 2020 Aug 1;396(10247):313-319. (PMID: 32534626)
      J Infect Dis. 2020 Oct 13;222(10):1607-1611. (PMID: 32860499)
      N Engl J Med. 2020 May 21;382(21):e62. (PMID: 32220207)
      Lancet Infect Dis. 2020 Apr;20(4):410-411. (PMID: 32087116)
      mSphere. 2018 Dec 12;3(6):. (PMID: 30541779)
      Proteomics. 2016 Apr;16(8):1271-9. (PMID: 26842269)
      MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):965-970. (PMID: 32701941)
    • الرقم المعرف:
      0 (Antibodies, Viral)
      0 (Immunoglobulin G)
      0 (Immunoglobulin M)
    • الموضوع:
      Date Created: 20210205 Date Completed: 20210216 Latest Revision: 20240330
    • الموضوع:
      20240330
    • الرقم المعرف:
      PMC7862219
    • الرقم المعرف:
      10.1038/s41598-021-82662-x
    • الرقم المعرف:
      33542329